Stimunity SAS

https://www.stimunity.com

Stimunity is a startup company from Institut Curie which develops biopharmaceuticals to treat patients that still do not respond to conventional immunotherapy in infectious disease and cancer. Stimunity focuses on the STING pathway, which is known to activate the innate immune system, and induce a T-CD8 response against pathogens and tumor cells. By addressing this target with a unique biologic approach which combines the the endogenous STING activator encapsulated in a Virus-Like Particle (VLP), Stimunity’s drugs are best-in-class. *

	Start	2016-02-24 established
	Predecessor	Institut Curie
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Person	Carlioz, Sylvain (Stimunity 201604 CEO)
	Person 2	Gros, Florent (Earlybird 202206 before Priothera + Novartis Venture Fund)

	Region	Paris
	Country	France
	Street	Rue du Faubourg Saint-Jacques
	City	75014 Paris
		Address record changed: 2020-12-02

Basic data	Employees	A: 1 to 10 (2016-04-13)

		* Document for »About Section«:

		Record changed: 2024-03-30

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)